Loading
A phase 1/2 trial of Adebrelimab, Cisplatin and SHR-A2102 in oesophageal cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer is a phase 1/2 interventional study registered as NCT06474468 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 148 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102；Adebrelimab；Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Cisplatin and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/